Evrima Technologies, Australia's leading clinical trial recruitment solutions provider, will be attending the World Vaccine Congress in Washington DC from April 1st to 4th, 2024. This globally renowned event, established in 2000, has evolved to become the largest and most esteemed gathering in the field of vaccines. Bringing together top researchers, policymakers, and other industry experts, the congress fosters discussions on vaccine science, research, manufacturing, and policy to advance disease prevention and enhance global public health.
At the 2024 World Vaccine Congress, Evrima Technologies’ Founder & CEO, Charlotte Bradshaw, will be hosting a booth and delivering a cornerstone talk on innovative strategies for optimising global vaccine clinical trial recruitment. Charlotte eagerly awaits this opportunity, saying:
"I am excited to attend the World Vaccine Congress and share insights on reaching diverse participant populations, collaborate with key thought leaders, and ultimately help streamline the journey of vital therapies from bench to bedside."
If you would like to meet with Charlotte at the World Vaccine Conference to discuss how Evrima’s clinical trial recruitment solutions can help you overcome barriers in vaccine trial recruitment, you can schedule a meeting one of three ways: book a meeting in the event app, email Charlotte directly, or message her on Linkedin.
Date: 1 - 4 April, 2024
Location: Walter E. Convention Centre, Washington DC
Booth #: 274
Date: 4 April, 2024
Time: 10:25 - 10:40 am
Room: 208AB
Subscribe to Evrima to stay up-to-date with our latest announcements, offerings, and breaking industry news.
Evrima Technologies is Australia’s leading clinical trial technology company. Using its suite of clinical trial recruitment software, management services, and other tailored solutions, Evrima rapidly connects a range of trial participants, researchers, and clinicians to expedite patient-centred clinical trials that contribute to medical research breakthroughs and better health outcomes - for everyone. Established in 2019, Evrima consistently delivers results across FIH to post-market trials in a broad range of therapeutic areas.